Singapore Ministry of Health addresses AI-developed drugs and patient data safeguards
A parliamentary response outlines regulatory approaches to AI drug development, clinical trials, and healthcare data protection in Singapore.
Singapore’s Ministry of Health has said that drugs developed with the use of AI will be subject to the same regulatory expectations as conventionally developed medicines, including requirements on quality, safety and efficacy.
The ministry made the statement in response to a parliamentary question on the regulation of AI-developed drugs, clinical trials and safeguards for patient data used in AI-related healthcare innovation.
It said the Health Sciences Authority’s approach is aligned with international regulatory principles on the responsible use of AI in drug development, including those outlined by the US Food and Drug Administration and the European Medicines Agency.
The ministry also said that patient data used for AI development is covered by existing data protection and cybersecurity safeguards, including obligations under Singapore’s Personal Data Protection Act to maintain patient confidentiality and prevent data leakage.
Authorities will continue to monitor developments in AI-related healthcare innovation and strengthen safeguards where necessary.
Why does it matter?
The response signals that Singapore is not creating a separate, lighter pathway for AI-developed medicines, but is applying existing drug safety standards while monitoring how AI changes research, development and clinical use. The issue is relevant for digital health governance because AI in drug development depends not only on regulatory approval of final products, but also on the protection of patient data used to train, test or validate health-related AI systems.
Would you like to learn more about AI, tech and digital diplomacy? If so, ask our Diplo chatbot!